It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
The focus now falls on first-line melanoma data with bempegaldesleukin plus Opdivo, due in early 2022.